RegeneRx Biopharmaceuticals, Inc. Release: New Study Confirms TB4 Improves Cardiovascular Function After Heart Attack; Collaboration With Pharmaceutical Firm Reproduces And Extends Findings Originally Published In Nature

BETHESDA, Md.--(BUSINESS WIRE)--Sept. 11, 2006--RegeneRx Biopharmaceuticals, Inc. (AMEX:RGN) today announced that a major pharmaceutical firm confirmed that thymosin beta 4 (TB4) significantly improved cardiac function when administered to laboratory animals immediately following induced myocardial infarction (heart attack). This data confirmed the 2004 publication in Nature that indicated statistically significant improvement in cardiac function in animals receiving TB4 after a heart attack compared to those receiving only a placebo.